Navigation Links
Patient Recruitment Begins in India for Phase 3 Diabetes Trial
Date:11/7/2008

BETHESDA, Md., Nov. 7 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial. "Now that enrollment efforts are underway in India, we believe that the Phase 3 trial will be completed on schedule as reported during the May 2008 Annual Shareholders Meeting. This truly represents a tremendous amount of hard work, both internally and externally, to achieve regulatory approval and patient recruitment in such a short period of time," said Randy W. Brown, Chief of Operations. Global enrollment is scheduled for completion by the end of the first quarter 2009, and the trial is scheduled to be completed in 2010.

Spherix Incorporated also announced the signing of a contract with Amarex, a Contract Research Organization (CRO) located in Germantown, MD, to oversee the work of two India CROs hired to execute the trial in India.

"It became quite clear that the trial was not executable solely in the United Sates with our known parameters; therefore, India became an obvious, viable solution. I now expect our ultimate deliverable, a new drug application, to be back on schedule," said Mr. Brown.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those
'/>"/>

SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
3. Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
4. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
5. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
6. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
9. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
(Date:9/22/2014)... , September 22, 2014 ... Line Development Market by Product (Equipment, Media and Reagents), ... Engineering & Regenerative medicine, Toxicity Testing, Research, Drug ... published by MarketsandMarkets, analyzes and studies the major ... Browse 114 market data tables and 64 ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... PARSIPPANY, N.J., Jan. 31, 2011 PDI, Inc. (Nasdaq: ... officer, is scheduled to present at the UBS 21st Annual Global ... at the Grand Hyatt New York. The live ... company,s website at http://www.pdi-inc.com . The webcast will be archived ...
... Calif., Jan. 31, 2011 OXIS International, Inc., (OTC ... today announced highly favorable final results from an initial ... patent-pending ERGOFLEX™ joint health formula, launched commercially ... of pain was statistically significant after as little as ...
Cached Medicine Technology:Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
(Date:9/22/2014)... By Amy Norton ... -- Tiny preemies may fare better when newborn intensive care ... time with their infants, a new study finds. Researchers ... were more alert and were less distressed when their NICU ... families. The findings, published online Sept. 22 in the ...
(Date:9/22/2014)... transplant seems futuristic, if not impossible. But with ... Defense, researchers at University of California, San Diego ... of an entire, functional eye a reality. , ... grail for vision restoration," said Jeffrey Goldberg, MD, ... colleagues at University of Pittsburg Medical Center and ...
(Date:9/22/2014)... 22, 2014 An inventor and anesthesiologist ... the problem of side-sleeping. "My lower arm always became ... designed a solution to this problem," she said. "It’s ... to have your arm 'fall asleep.'" , The Sleeping ... her side more comfortably. It avoids pain and restlessness ...
(Date:9/22/2014)... 22, 2014. Kessler researchers have published a pilot ... wellness program in people with multiple sclerosis (MS). ... health, perceived stress, and pain. "Development and ... living with MS: Description and outcomes" was epublished ... International Journal of MS Care (doi: ...
(Date:9/22/2014)... News) -- Scans of young children,s brains might ... finding could potentially allow doctors to identify those ... preliminary research suggests. "Early identification and interventions ... well as most neurodevelopmental disorders," the study,s senior ... child and adolescent psychiatry at University of California, ...
Breaking Medicine News(10 mins):Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... authored by two Memorial University faculty members published in ... the Public Library// of// Science (PLoS). Drs. Amin A. ... the paper, entitled, "Prevalence of depression among house holds ... the mental health policy." ,Dr. Muhammad Gadit ...
... allow a pioneering doctor, currently under house arrest in Henan ... award for her work on behalf// of HIV/AIDS patients, it ... had permission to travel," retired professor Gao Yaojie, 79, told ... holding her under house arrest for two weeks. ...
... found supporting evidence to implicate insulin-like growth factor receptor ... ,In a previous research, Terry J. Smith, M.D. and ... immunoglobulins and IGF-1R as a cause of inflammation and ... , The discovery of these mechanisms in ...
... University have developed a novel spraying method for delivering ... a new low-cost and scaleable technique that offers needle-free ... methods. The process could one day provide a better ... related spread of HIV/AIDS in the developing world. ...
... If you are cooking with garlic, crush the pods first ... benefits and medicinal properties are well known. It has long ... folklore for preventing everything from the common cold and flu ... herbal medicine and it contains compounds shown to help prevent ...
... on Friday plan to distribute 250,000 city-branded condoms as ... the spread of HIV// and other sexually transmitted infections, ... purple and yellow package is printed in English and ... Coming together to stop HIV in D.C.' The first ...
Cached Medicine News:Health News:A Single Biological Mechanism Behind Several Autoimmune Disorders 2Health News:Scientists Partner to Develop and Distribute New Tuberculosis Vaccine 2Health News:Free Condoms Distribution to Prevent HIV in Washington 2
... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
... Temporary, Transvenous Pacing Lead System Features an ... lubricated guide catheter. The system is designed ... The system is disposable, for temporary single ... of 7 days or less. The lead ...
... system provides an ideal solution for ... laboratory, satellite lab and the clinic ... method with wedge-smear technology, the ADVIA ... in a safe enclosed environment. The ...
It is a cardio-pulmonary exercise testing device....
Medicine Products: